scholarly journals A novel mutation in a newborn baby leading to glycogen storage disease type Ia

2018 ◽  
Vol 21 (2) ◽  
pp. 55-57
Author(s):  
S Dorum ◽  
O Gorukmez

Abstract Glycogen storage disease type Ia (GSD1A) is caused by mutations in the G6PC gene. The G6PC gene was first cloned in 1993. Since then, many different mutations have been identified leading to this disease. Hepatomegaly is one of the important clinical manifestations of the disease. A 23-day-old girl was admitted to the hospital due to respiratory distress. Her physical examination was normal except for tachypnea. She had hypoglycemia, lactic academia, hyperlipidemia and hyperuricemia. With these clinical findings, GSD1A was considered in the patient and the diagnosis was genetically confirmed. By direct sequencing of the G6PC gene, we identified a novel homozygous variation (c.137T>G/p.Leu46Arg) in the patient and the healthy mother and father were heterozygotes for the variant. Here we present a case with a novel homozygous missense mutation c.137T>G/p.Leu46Arg in the G6PC gene leading to GSD1A clinical findings except early hepatomegaly. These findings expand the spectrum of causative mutations, and clinical findings in GSD1A.

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Andrew Specht ◽  
Laurie Fiske ◽  
Kirsten Erger ◽  
Travis Cossette ◽  
John Verstegen ◽  
...  

A canine model of Glycogen storage disease type Ia (GSDIa) is described. Affected dogs are homozygous for a previously described M121I mutation resulting in a deficiency of glucose-6-phosphatase-α. Metabolic, clinicopathologic, pathologic, and clinical manifestations of GSDIa observed in this model are described and compared to those observed in humans. The canine model shows more complete recapitulation of the clinical manifestations seen in humans including “lactic acidosis”, larger size, and longer lifespan compared to other animal models. Use of this model in preclinical trials of gene therapy is described and briefly compared to the murine model. Although the canine model offers a number of advantages for evaluating potential therapies for GSDIa, there are also some significant challenges involved in its use. Despite these challenges, the canine model of GSDIa should continue to provide valuable information about the potential for generating curative therapies for GSDIa as well as other genetic hepatic diseases.


2017 ◽  
Vol 96 (1) ◽  
pp. 19-23 ◽  
Author(s):  
SHEKARI KHANIANI MAHMOUD ◽  
AZIZ KHORRAMI ◽  
MANDANA RAFEEY ◽  
ROBABEH GHERGHEREHCHI ◽  
MANSOORI DERAKHSHAN SIMA

Sign in / Sign up

Export Citation Format

Share Document